(Z)-Ligustilide
Based on 5 publication(s) in Google Scholar
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.
For research use only. We do not sell to patients.
- Purity: 98.58%
- CAS No.: 81944-09-4
- Formula: C12H14O2
- Molecular Weight:190.24
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (Z)-Ligustilide
More
Customer Validation & Images
-
IF
-
WB
-
In Vivo Efficacy Study
-
RT-PCR
-
Cell Proliferation/Viability Assay
Biological Activity
|
ERα |
Z-ligustilide (25 and 100 µM, 24 hours) can effectively inhibit oleic acid-induced lipid accumulation in HepG2 cells, suppress fatty acid uptake and esterification, and has potential anti-fatty liver effects[2]. Z-ligustilide (10-50 μM, 72 hours) can significantly enhance the sensitivity of ERα-negative breast cancer cells to Tamoxifen (HY-13757A) by restoring the expression of ERα[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 cells
-
Concentration:25 and 100 µM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced the mRNA expression of FATP5 and DGAT2 genes.
-
Cell Line:HepG2 cells
-
Concentration:25 and 100 µM
-
Incubation Time:24 h
-
Result:Significantly reduced the expression level of DGAT2 protein.
-
Cell Line:MDA-MB-231, MDA-MB-453, HS578t cells
-
Concentration:10, 25, 50 μM
-
Incubation Time:72 h
-
Result:After co-administration with Tamoxifen (HY-13757A), significantly inhibited cell proliferation, promoted cell apoptosis, and induced cell cycle arrest in the S phase and G2/M phase.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:High-fat diet (HFD)-induced fatty liver model in male C57BL/6 mice[2]
-
Dosage:50 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 6 weeks
-
Result:Significantly reduced high-fat diet (HFD)-induced hepatic fat accumulation in mice, as confirmed by hepatic TG assay, H&E staining, and Oil Red O staining, showing a marked decrease in liver lipid content. Significantly inhibited the expression of fatty acid uptake-related genes CD36 and DGAT2, and reduced the expression of SREBP1c and its downstream target genes FAS and SCD1, thereby decreasing lipid production in the liver.
Chemical Information
-
CAS No. 81944-09-4
-
Appearance Liquid (Density: 1.10±0.1 g/cm3)
-
Molecular Weight 190.24
-
Formula C12H14O2
-
Color Colorless to light yellow
-
SMILES
O=C1O/C(C2=C1C=CCC2)=C\CCC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Z-Ligustilide's antidepressant effects in adolescent depression involve the PTEN-induced putative kinase 1 (PINK1) - protein kinase A (PKA)- Na+/Ca2+ exchanger (NCLX) pathway, facilitating mitochondrial endosymbiosis and promoting mitophagy in microglia. [Abstract]2025 Dec:149:157494. PMID: 41218379
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494. [Abstract]
IF double staining for PINK1 (green) and Iba-1 (red) in the hippocampal CA1 region, and semi-quantitation in bar chart. Scale bar = 75 µm, n = 6. IF staining revealed an increase in the colocalization of PINK1 and Iba-1 in the hippocampal CA1 region following (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) administration.
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494. [Abstract]
Expression of PINK1 by WB and semi-quantitation in bar chart (n = 5). WB results demonstrated that (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) dose-dependently upregulated the level of PINK1 (p < 0.01).
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494. [Abstract]
Immobile times in the FST (n = 10). The results demonstrated that (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) markedly reduced the immobility duration in adolescent rats (p < 0.01).
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494. [Abstract]
The relative mRNA levels of IL-1β, IL-6 and IL-4, IL-10 in BV2 cells by (Z)-Ligustilide (Z-LIG, 10, 20, 40 µM; 15 h) (n = 6). Real-time PCR analysis revealed that treatment with 20 and 40 μM Z-LIG significantly inhibited the mRNA expression of pro-inflammatory cytokines IL-6 and TNF-α while promoting the expression of the anti-inflammatory cytokines IL-4 and IL-10.
-
Vet Microbiol
Z-Ligustilide restricts rabies virus replication by inducing ferroptosis through the ACSL4-LPCAT3-POR pathway. [Abstract]2024 Sep 23:298:110260. PMID: 39316946
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 Sep 23:298:110260. [Abstract]
N2a cells were treated with a series of concentrations of (Z)-Ligustilide for 24 h; cell viability was determined with the Cell Counting Kit-8 (CCK-8), and the cytotoxic concentration 50% (CC50) was calculated. The results indicated that the CC50 of (Z)-Ligustilide in N2a cells was 429.9 μM.
(Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 Sep 23:298:110260. [Abstract]
N2a cells were treated with a series of concentrations of (Z)-Ligustilide for 24 h, supernatants were harvested, virus titers were determined, and the viral inhibitory concentration 50% (IC50) was calculated separately (n=3). The results indicated that the IC50 of (Z)-Ligustilide for RABV infection on N2a cells was 71.93 μM.
-
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (525.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rodrigues AMS, et al. The antifungal potential of (Z)-ligustilide and the protective effect of eugenol demonstrated by a chemometric approach. Sci Rep. 2019 Jun 19;9(1):8729. doi: 10.1038/s41598-019-45222-y [Content Brief]
[2]. Lee W, et al. Z-ligustilide and n-Butylidenephthalide Isolated from the Aerial Parts of Angelica tenuissima Inhibit Lipid Accumulation In Vitro and In Vivo. Planta Med. 2019 Jul;85(9-10):719-728. [Content Brief]
[3]. Ma H, et al. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa. Oncotarget. 2017 Apr 25;8(17):29328-29345. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.2565 mL | 26.2826 mL | 52.5652 mL | 131.4129 mL |
| 5 mM | 1.0513 mL | 5.2565 mL | 10.5130 mL | 26.2826 mL | |
| 10 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | 13.1413 mL | |
| 15 mM | 0.3504 mL | 1.7522 mL | 3.5043 mL | 8.7609 mL | |
| 20 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL | 6.5706 mL | |
| 25 mM | 0.2103 mL | 1.0513 mL | 2.1026 mL | 5.2565 mL | |
| 30 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | 4.3804 mL | |
| 40 mM | 0.1314 mL | 0.6571 mL | 1.3141 mL | 3.2853 mL | |
| 50 mM | 0.1051 mL | 0.5257 mL | 1.0513 mL | 2.6283 mL | |
| 60 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 80 mM | 0.0657 mL | 0.3285 mL | 0.6571 mL | 1.6427 mL | |
| 100 mM | 0.0526 mL | 0.2628 mL | 0.5257 mL | 1.3141 mL |
(Z)-Ligustilide Related Classifications
HY-N0401A Related Classifications
Powered by Bioz